Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)


 0.05 (4.39%)

Market Cap$16,262,569

02/19/19  10:13 a.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $1.19 with a 52 week high of $11.43 and a 52 week low of $0.57.

Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update


Read More

Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update


Read More

Gemphire Therapeutics Announces Workforce Reduction


Read More

There are currently no events scheduled.